Wayne R. Godfrey - Concepedia

Author

Wayne R. Godfrey

Stanford University

Also Known As

W R Godfrey, W. Godfrey, W.R. Godfrey, Wayne Godfrey, Wayne R Godfrey, Wayne R. Godfrey, Wayne Russell Godfrey

Publications

5.6K

Citations

H-Index

Concepts

All Affiliations

Stanford University Washington University in St. Louis Cornell University Gilead Sciences (United States)Sarah Cannon

About

Wayne R. Godfrey is an author at Stanford University specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	797
2	Immunology	9	9	698
3	Cell Biology	4	4	569
4	Health Sciences	2	2	23
5	Cellular Physiology	1	1	99

Wayne R. Godfrey

Publications

5.4K

Citations

H-Index

Page 1

	Year	Citations
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma Ajay K. Gopal, Brad S. Kahl, Sven de Vos, New England Journal of Medicine	2014	1K
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer Philip W. Kantoff, Thomas Schuetz, Brent A. Blumenstein, Journal of Clinical Oncology	2010	969
A Novel Five-Transmembrane Hematopoietic Stem Cell Antigen: Isolation, Characterization, and Molecular Cloning Sheri Miraglia, Wayne R. Godfrey, Amy H. Yin, Blood	1997	944
Cord blood CD4+CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function Wayne R. Godfrey, Darrin J. Spoden, Ying G. Ge, Blood	2004	295
In vitro–expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell–stimulated MLR cultures Wayne R. Godfrey, Ying G. Ge, Darrin J. Spoden, Blood	2004	275
Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. Wayne R. Godfrey, F F Fagnoni, M A Harara, The Journal of Experimental Medicine Adaptive Immune SystemHuman Immunoglobulin FcImmunologyCell DeathPathology	1994	273
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL) Brad S. Kahl, Stephen E. Spurgeon, Richard R. Furman, Blood	2014	247
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma Ian W. Flinn, Brad S. Kahl, John P. Leonard, Blood	2014	206
Robust B Cell Immunity but Impaired T Cell Proliferation in the Absence of CD134 (OX40) Susanne Pippig, Claudia Peña-Rossi, James P. Long, The Journal of Immunology T Cell ReactivityLymphocyte DevelopmentAdaptive Immune SystemTnf Receptor FamilyT-regulatory Cell	1999	162
Selective depletion of myelin–reactive T cells with the anti–OX–40 antibody ameliorates autoimmune encephalomyelitis Andrew D. Weinberg, Dennis Bourdette, Timothy J. Sullivan, Nature Medicine ImmunodeficienciesImmunologyImmune RegulationImmunodominanceSelective Depletion	1996	156

Page 1